A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).
Wu J, Atkinson E, Leichman L, Patel H, Iqbal S, Du K, Bizekis C, Goldberg J, Thomas C, Cohen D, Becker D, Siolas D, Beri N, Oberstein P, Ku G. A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Journal Of Clinical Oncology 2020, 38: 372-372. DOI: 10.1200/jco.2020.38.4_suppl.372.Peer-Reviewed Original ResearchEsophageal squamous cell carcinomaAdvanced esophageal squamous cell carcinomaClinical CRRadiation therapyPhase I/II studyCarboplatin/paclitaxelEfficacy of nivolumabGrade 2 esophagitisGrade 3/4 AEsGrade 5 toxicityOverall survival benefitPhase II portionSquamous cell carcinomaConcurrent chemoRTManageable toxicityLast dosePrimary endpointII studyUnacceptable toxicityElevated ASTSurvival benefitCell carcinomaChemoRTGrade 3Nivolumab